Alteogen gains approval to start aflibercept biosimilar trial in Korea

Biosimilars/News | Posted 21/06/2019 post-comment0 Post your comment

South Korean biologicals company Alteogen announced on 22 May 2019 that it had gained approval from the Korean Ministry of Food and Drug Safety (MFDS) to initiate a clinical trial for its aflibercept biosimilar, ALT‑L9.

Age-related macular degeneration V15b19

Aflibercept is used to treat eye diseases, including neovascular age-related macular degeneration (AMD), macular oedema secondary to retinal vein occlusion, diabetic macular oedema, and diabetic retinopathy.

The phase I, randomized, double-blind trial will be conducted in one of the five major hospitals in Korea. It will evaluate the safety, efficacy and pharmacokinetics in patients with wet age-related macular degeneration in comparison to the originator biological Eylea.

Alteogen says that this ‘domestic clinical trial of Eylea biosimilar is the first in Korea, which shows our potential as the first runner’. The company also intends to initiate a phase III trial during 2019 ‘to build the foundation for entry into the global market including the US, Europe and Japan’. The company is also reportedly ‘receiving many inquiries regarding the technology transfer from global pharmaceutical companies around the world’.

Alteogen was granted a process patent for its method of producing an aflibercept biosimilar in January 2019. The company expects this patent to further strengthen its competitiveness in Eylea biosimilar development [1].

Other companies also working on aflibercept biosimilars include US generics giant Mylan and partner Momenta Pharmaceuticals [2], US firm Coherus and Germany-based Formycon/Santo Holding.

Related article
Alteogen gains patent on SC trastuzumab biosimilar

1. GaBI Online - Generics and Biosimilars Initiative. Alteogen wins process patent for aflibercept biosimilar []. Mol, Belgium: Pro Pharma Communications International; [cited 2019 Jun 21]. Available from: 
2. GaBI Online - Generics and Biosimilars Initiative. Mylan/Momenta announce development strategy for aflibercept biosimilar []. Mol, Belgium: Pro Pharma Communications International; [cited 2019 Jun 21]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2019 Pro Pharma Communications International. All Rights Reserved.

Source: Alteogen

comment icon Comments (0)
Post your comment
Related content
EC approval of first ustekinumab biosimilar Uzpruvo
Biosimilars/News Posted 16/01/2024
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010